Compare Procter & Gamble Health with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs ALEMBIC LTD - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH ALEMBIC LTD PROCTER & GAMBLE HEALTH/
ALEMBIC LTD
 
P/E (TTM) x 53.1 67.6 78.4% View Chart
P/BV x 4.8 2.4 199.9% View Chart
Dividend Yield % 9.9 0.4 2,326.1%  

Financials

 PROCTER & GAMBLE HEALTH   ALEMBIC LTD
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
ALEMBIC LTD
Mar-18
PROCTER & GAMBLE HEALTH/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs3,54972 4,929.2%   
Low Rs1,30134 3,838.6%   
Sales per share (Unadj.) Rs511.44.7 10,880.3%  
Earnings per share (Unadj.) Rs61.36.1 1,004.1%  
Cash flow per share (Unadj.) Rs74.06.2 1,185.1%  
Dividends per share (Unadj.) Rs440.000.20 220,000.0%  
Dividend yield (eoy) %18.10.4 4,803.4%  
Book value per share (Unadj.) Rs927.840.7 2,281.7%  
Shares outstanding (eoy) m16.60267.03 6.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.711.3 42.1%   
Avg P/E ratio x39.68.7 456.1%  
P/CF ratio (eoy) x32.88.5 386.5%  
Price / Book Value ratio x2.61.3 200.7%  
Dividend payout %717.93.3 21,909.2%   
Avg Mkt Cap Rs m40,25714,139 284.7%   
No. of employees `0001.1NA-   
Total wages/salary Rs m1,313207 632.9%   
Avg. sales/employee Rs Th7,486.7NM-  
Avg. wages/employee Rs Th1,157.6NM-  
Avg. net profit/employee Rs Th897.2NM-  
INCOME DATA
Net Sales Rs m8,4901,255 676.4%  
Other income Rs m244370 65.9%   
Total revenues Rs m8,7341,625 537.3%   
Gross profit Rs m1,482111 1,333.6%  
Depreciation Rs m21138 558.7%   
Interest Rs m02 0.0%   
Profit before tax Rs m1,514442 342.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m56324 2,348.6%   
Profit after tax Rs m1,0171,630 62.4%  
Gross profit margin %17.58.9 197.2%  
Effective tax rate %37.15.4 685.2%   
Net profit margin %12.0129.8 9.2%  
BALANCE SHEET DATA
Current assets Rs m15,3431,867 821.8%   
Current liabilities Rs m1,960591 331.6%   
Net working cap to sales %157.6101.6 155.1%  
Current ratio x7.83.2 247.8%  
Inventory Days Days4994 51.7%  
Debtors Days Days2874 38.7%  
Net fixed assets Rs m1,2091,791 67.5%   
Share capital Rs m166534 31.1%   
"Free" reserves Rs m15,23510,324 147.6%   
Net worth Rs m15,40110,858 141.8%   
Long term debt Rs m041 0.0%   
Total assets Rs m17,59511,591 151.8%  
Interest coverage xNM260.9-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.1 445.6%   
Return on assets %5.814.1 41.1%  
Return on equity %6.615.0 44.0%  
Return on capital %10.315.2 67.5%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m1,63619 8,434.5%   
Fx outflow Rs m4,368264 1,655.7%   
Net fx Rs m-2,732-244 1,117.7%   
CASH FLOW
From Operations Rs m-1,304236 -552.9%  
From Investments Rs m12,697-224 -5,668.4%  
From Financial Activity Rs m-301-27 1,129.7%  
Net Cashflow Rs m11,093-15 -74,952.0%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.2 9,100.0%  
FIIs % 1.0 9.7 10.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 26.1 111.5%  
Shareholders   28,591 54,701 52.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  ELDER PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Telecom and Automobiles Stocks Lose(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is down 0.1%.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Oct 18, 2019 11:19 AM

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH - PLETHICO PHARMA COMPARISON

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS